Anticoagulation in AF with Rheumatic Heart Disease Among | UPDATES IN MEDICINE
Anticoagulation in AF with Rheumatic Heart Disease
Among patients with rheumatic heart disease and atrial fibrillation who received a vitamin K antagonist or rivaroxaban, the rate of stroke, systemic embolism, MI, or death from vascular or unknown causes was lower with a VKA, without increased bleeding.
